Business

Voithru Wraps Up 2nd t ōtus Translation Contest with Great Success

Record-Breaking 3,586 Translators Participated in tōtus Translation Contest SEOUL,South Korea,Feb. 17,2025-- On February 8,2025,VOITHRU,a leader in cultural content translation,successfully concluded

02-18

Minish Holds First Seminar in Japan with Great Success - Over 100 Dentists in Attendance

"Impressed by Extensive Full-Mouth Rehabilitation Cases","Anti-Aging Effects Highly Praised"

02-18

Reolink Makes Wireless Security Camera Systems Accessible to All Homes

LOS ANGELES,Feb. 17,2025-- Every homeowner deserves peace of mind when it comes to home security. Reolink,an innovative leader in intelligent visual technology for the home,brings the Wireless Securi

02-18

Duke and Duke-NUS forge new frontiers in climate health research with S$1million funding

The two institutions awarded more than S$1 million to accelerate five promising areas of research collaboration

02-17

ATxEnterprise 2025 Celebrates Five Years of Powering Enterprise Technology, Cybersecurity, and Digital Transformation

SINGAPORE,Feb. 14,2025-- ATxEnterprise (ATxE) 2025,a flagship event of Asia Tech x Singapore (ATxSG),returns for its fifth year,providing a strategic platform for enterprises,governments,and technolo

02-17

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 14th + KARMAN POPS DOUBLE DIGIT IPO

NEW YORK,Feb. 14,2025-- The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today\'s NYSE Pre-market update for market insight

02-17

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

SUZHOU,China,Feb. 13,2025-- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 bi

02-14

DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development

SEOUL,South Korea,Feb. 13,2025-- DAAN Biotherapeutics,a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies,has signed an exclusive licensing agreement w

02-14

Year of the Snake Celebrations Bring Lively Festivities to Cangzhou

CANGZHOU,China,Feb. 13,2025-- A news report from xinhuanet: The Year of the Snake ushers in an energetic Spring Festival in Cangzhou,Hebei Province. Locals and tourists alike are reveling in the festi

02-14

AI is turbocharging media production and democratizing creativity, but challenges persist for the industry, reveals new MIT Technology Review Insights research report

Digital media standards underlie every advance CAMBRIDGE,Mass.,Feb. 13,2025-- A new report byMIT Technology Review Insights explores how emerging tech is remaking the media and entertainment industri

02-14

Home Previous 28 29 30 31 32 33 34 Next Tail

10 Items Per Page (Page 31 / 154) Total 1533 Items

Newest

1Cangxi County Holds 2026 New Year's Cultural Performance for the Public

Cangxi County Holds 2026 New Year's Cultural Performance for the Public

2The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

3The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully

4Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange

5Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference

6Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement

©copyright 2009-2020 Singapore Info Map